Lance Grady Discusses Continued At-Home Administration of Specialty Pharmaceuticals

After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.

After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.

Transcript

What services will stay online for patients on specialty drugs in the post-pandemic world?

Well, I think under the commercial benefit, the ability to have a homebound administration is really critical. Do we see that homebound administration always be self-administered meaning by the patient, or will we see, you know, caregiver administration or home administration via IV [intravenous], but coordinated by say a specialty pharmacy? I think there is a real opportunity there for that to stick or remain.

Does that extend over into government books of business where those products are usually physician administered? I think that remains to be seen as to how that will continue to evolve or expand post the PHE [public health emergency]. But certainly, flexibility of choice and the beneficiary having that choice could line up with a plan of interest in more preferred or mandated step therapy of products that are self-administered versus those that are physician administered or those that might be administered in a hospital outpatient setting.

So, I think those incentives start to line up the patient might not want to ambulate, the plan may want to have that patient managed in a less acute setting of care. Does that lead to more self administer? Probably so. Does that lead to more pharmacy-coordinated physician or nurse administered in home? Probably so as well.